Assessing early-stage healthcare ventures is a critical step in seed stage investing. Because these companies are still in the early stages of development, there may be limited data available to evaluate their potential for success. As a result, investors must conduct extensive due diligence to assess the viability of an investment opportunity.

​

Key Factors to Consider

When assessing early-stage healthcare ventures, there are several key factors that investors should consider:

​

Management Team

The passion and quality of the management team is another critical factor to consider. Investors should look for teams with deep industry knowledge and experience, as well as strong leadership skills. They should also assess the team's ability to execute on its business plan and navigate technical, clinical, regulatory, and commercial hurdles.

​

Market Potential

One of the most important factors to consider when evaluating a healthcare startup is its potential market size. Investors should look for startups that are operating in large and growing markets, with significant unmet needs or opportunities for innovation. They should also assess the competitive landscape to determine whether the startup has a unique value proposition that will enable it to capture market share.  Healthcare is unique in that the end beneficiary (e.g. patient) is many times different from the implementer/user (healthcare professional) who is different from the stakeholder footing the bill (e.g. insurance company).  

​

Product Development

Investors should also evaluate the startup's product development strategy. They should look for evidence that the startup has a clear understanding of the problem it is trying to solve and has developed a viable solution (e.g. feasibility) and has a robust plan to bring to market (e.g. new product development). This may involve understanding of the product's intended use, assessing the quality of its research and development team, evaluating any early data supporting the value proposition, and understanding the development plan (including clinical and regulatory goal) with milestones.

​

Commercial Readiness 

Revenue and growth are the lifeblood of any early stage healthcare company, and the pathway from product to adoption is a critical one.   Evaluating the go to market strategy, core product positioning, pricing and manufacturing, and targeting of early customers, along with validate that the product is driving value in the marketplace  is key to being able to drive confidence in the early stage plan. 

​

Intellectual Property 

Intellectual property (IP) is a critical asset for any early stage medical device company. IP can help to create a barrier to entry for competition by preventing others from developing and commercializing similar products.  Traditionally, IP due diligence has focused on two key areas: freedom to operate (FTO) and blocking. FTO analysis assesses whether the company's IP portfolio is likely to be infringed by the IP of others. Blocking analysis assesses whether the company's IP portfolio is likely to prevent others from developing and commercializing similar products.

While FTO and blocking analysis are still critical, it is important to also consider the context of the IP landscape. For example, there may be multiple approaches to algorithms, usability, and workflow, which could make it difficult for one company to obtain broad IP protection. Additionally, early adopters of a new technology may create a separate barrier to entry by developing their own IP.  By considering the context of the IP landscape, companies can develop a more comprehensive IP strategy that will help them to protect their intellectual property and achieve their business goals.

​

Financials

Finally, investors should carefully assess the startup's financials and how they plan on using capital. This may involve reviewing financial projections, assessing burn rates and cash flow against their goals, and evaluating the startup's fundraising history. Investors should also consider the potential for future funding rounds and the dilution that may result from those rounds.  The goal is to understand the pathway and forecast and eventual arrive at a valuation.  

​

Due Diligence

Conducting thorough due diligence is critical when assessing early-stage healthcare ventures.  This is a critical part of Netra's value proposition both in terms of process and the use of its network to ascertain these dimensions.  

It is important to note that due diligence is an ongoing process, and investors must remain vigilant even after making an initial investment. They should monitor the startup's progress against key milestones, assess changes in the market landscape, and remain alert to emerging risks that could impact the success of their investment.  Netra typically plays some form of advisory role, which allows the principles to stay close to when portfolio companies meet milestones and need guidance at critical steps.